NCT04338269 2026-03-19
CONTACT-03
Hoffmann-La Roche
Phase 3 Terminated
Clinical Trials
11 trialsNCT02243605 2026-03-18
Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03375320 2026-03-18
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04079712 2026-03-18
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
NCT04091750 2026-03-03
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
Georgetown University
Phase 2 Active not recruiting
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT03468218 2026-01-23
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
Emory University
Phase 2 Active not recruiting
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT04022343 2026-01-05
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
Phase 2 Active not recruiting
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed